IGM Biosciences — Investor Presentation (December 2020)
39 slides from IGM Biosciences's investor presentation, Dec 7, 2020
Slide 1: Pioneering the Development of Engineered IgM Antibodies
Pioneering the Development of Engineered IgM Antibodies Corporate Presentation December 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the “Company,” “we” or “our”) with respect to the Company’s future financial conditio
Slide 3: IGM Overview
IGM Overview Global leaders in the development of engineered IgM antibodies for therapeutic use Lead Programs Proprietary IGM antibody technology: 27 patent families Strategy: extend our global leadership in the development of engineered IgM antibodies $180.2M Cash and Investments Balance, September
Slide 4: IGM's Wholly-Owned Oncology Pipeline
Mode Target Indications Worldwide Commercial Rights T cell Engagers CD123 x CD3 Acute Myeloid Leukemia CD38 x CD3 Multiple Myeloma Multiple Targets x CD3 Multiple Solid Tumors Receptor Cross- linking Agonists OX40 Solid and Hematologic Malignancies GITR Mode Target Indications Phase of Development W
Slide 5: Why IgM? Structural comparison of IgG and IgM antibodies
Why IgM? Structural comparison of IgG and IgM antibodies Greatly superior total binding power (Avidity) Target binding domains Constant domains Joining chain (J chain) LEGEND IgG IgM
Slide 6: Asymmetric Bispecific Technology
CD20 IgM plus CD3 on J-chain scFv - J chain IgM Asymmetric Bispecific Technology High avidity, potent T cell dependent cytotoxicity
Slide 7: IGM-2323 Bispecific T Cell Engagement
IGM-2323 Bispecific T Cell Engagement T cell directed cellular cytotoxicity (TDCC)
Slide 8: IGM-2323 Dual Mechanism of Action
IGM-2323 Dual Mechanism of Action Complement dependent cytotoxicity (CDC)
Slide 9: Dual Mechanisms of Action: TDCC plus CDC
Dual Mechanisms of Action: TDCC plus CDC CDC only IGM-2323 TDCC + CDC Modified IGM-2323 B cell depletion (CD19+) in non-human primate studies CDC only versus TDCC + CDC
Slide 10: IGM-2323 Dose Escalation Clinical Trial
IGM-2323 Dose Escalation Clinical Trial Dose escalation phase IGM-2323 (0.5 mg) IGM-2323 (2.5 mg) IGM-2323 (10 mg) IGM-2323 (30 mg) IGM-2323 (100 mg)† IGM-2323 (300 mg) IGM-2323 (1000 mg) IGM-2323 (50/300 mg)* IGM-2323 (50/100 mg)* Single patient cohorts Dose escalation Titration dosing* MABEL n=1 n
Slide 11: Initial Insights from Patients: Efficacy
Initial Insights from 14 Patients: Efficacy Efficacy Headlines 9 of 14 patients showed reduction in tumor size, despite relatively low doses and short follow-up at higher doses Evidence of activity across all initial dose cohorts, starting at 0.5 mg Intra-patient dose escalation allowed after higher
Slide 12: Initial Insights from Patients: Safety
Initial Insights from 14 Patients: Safety Safety Headlines Minimal pre-treatment: 10 mg of dexamethasone prior to first dose; optional on subsequent doses No neurotoxicity No Dose Limiting Toxicities Dosing cohorts: 0.5, 2.5, 10, 30 and 50/100 (N=14) 3 patients had CRS (21%) All Grade 1, transient,
Slide 13: Documented Pseudo-Progression, Prior to Response
Documented Pseudo-Progression, Prior to Response DLBCL patient, post CAR-T DLBCL: diffuse large B-cell lymphoma; PET: positron emission tomography; R/R: relapsed/refractory; SPD: sum of the products of diameters. Biopsy of new PET-avid lesion at 8 weeks shows intense T-cell infiltration with scant l
Slide 14: DLBCL Post CAR-T, Post Stem Cell Transplant, Case Study
DLBCL Post CAR-T, Post Stem Cell Transplant, Case Study Cytokine release profile IFNg TNFa IL-6 IFNγ interferon-gamma; IL-6: interleukin-6; TNFa: tumor necrosis factor alpha. Data cut off: October 30, 2020 IFNγ dominant cytokine release profile
Slide 15: Follicular Lymphoma in 50/100 Dose Cohort (updated: 2/2 CR)
Follicular Lymphoma in 50/100 Dose Cohort (updated: 2/2 CR) After data cut off of October 30, 2020: PET/CT Complete Response (CR) Change in SPD from Baseline (%) 25 0 -25 -75 FL Pt 1: PR, lesion size returned to below normal, minor residual PET signal after data cut off of October 30, 2020: PET/CT C
Slide 16: Follicular Lymphoma in 50/100 Dose Cohort (updated: 2/2 CR)
Follicular Lymphoma in 50/100 Dose Cohort (updated: 2/2 CR) After data cut off of October 30, 2020: PET/CT Complete Response (CR) CR FL Pt 1: PR, lesion size returned to below normal, minor residual PET signal after data cut off of October 30, 2020: PET/CT CR 69 yo/Female; 4 prior treatments, includ
Slide 17: Extended Duration of Activity – Deepening Responses Over Time
Extended Duration of Activity – Deepening Responses Over Time Data cut off: October 30, 2020 Patients with evidence of tumor size reduction shown (n=9) 0 10 20 30 40 Time (weeks) 25 0 -25 -75 Change in SPD from Baseline (%)
Slide 18: IGM-2323 Pharmacokinetics
IGM-2323 Pharmacokinetics IGM-2323 PK is approximately dose proportional PK parameters are within expected range based on preclinical modeling Sustained drug levels in multiple patients at dose levels > 30 mg No drug-induced anti-drug antibodies observed to date LLOQ: lower limit of quantitation; t1
Slide 19: Potential Best-in-Class Safety Profile
Potential Best-in-Class Safety Profile Minimal pre-treatment to date 10 mg dexamethasone prior to first dose Optional on subsequent doses No neurotoxicity at any dose to date 14 patients dosed at 0.5, 2.5, 10, 30 and 50/100 mg 3 patients had CRS (21%) All Grade 1, transient, chills/fever May be rela
Slide 20: IGM-2323 Leads to IFNg Secretion
IGM-2323 Leads to IFNg Secretion IFN��-dominant cytokine secretion with little measurable circulating IL-6 or TNFa in most patients differs from other T cell engagers Data suggest preservation/strengthening of T cell activation in patients treated w/ IGM-2323 vs. step-dosing effect seen with other T
Slide 21: 2021 Clinical Goals for IGM-2323
2021 Clinical Goals for IGM-2323 Establish Recommended Phase 2 Dose (RP2D) Commence expansion trials in resistant/refractory NHL Commence initial clinical trial in CLL Commence clinical trial in 1L NHL Combination with R-CHOP ASH 2020 RP2D A. Global Expansion in well defined R/R DLBCL and R/R FL C.
Slide 22: IGM-2323 Key Takeaways
IGM-2323 Key Takeaways Strong activity seen at low doses 9 of 14 patients in early-stage dose escalation showed lesion size reduction Activity across dose cohorts from 0.5 mg initial dose to 50/100 mg Stronger activity shown in higher dose cohorts On track to complete 50/300 dose cohort enrollment b
Slide 23: Patient Baseline Characteristics and Disposition
Patient Baseline Characteristics and Disposition (N=16 Total Enrolled) Characteristic Follicular NHL/ Marginal Zone NHL (n=10) DLBCL/ Mantle Cell (n=6) Median age (range) 66.5 (47–75) 61 (46–82) Histology FL=8 MZL=2 DLBCL=4 MCL=2 Prior therapies, median (range) 4 (2–6) 4 (2–6) Prior ASCT, n (%) 2 (2
Slide 24: AE Summary: Treatment-Emergent AEs Occurring in ≥ 20% of Patients
AE Summary: Treatment-Emergent AEs Occurring in ≥ 20% of Patients (n=16 total enrolled) a4 out of 5 patients with creatinine increase were assessed as unrelated to study treatment, per investigator bCRS grading by ASTCT criteria; all CRS patients are also captured under pyrexia and/or chills. c3 of
Slide 25: TNFr Superfamily: Trimerizing Agonists
TNFr Superfamily: Trimerizing Agonists Apoptosis Cell Death Strong Apoptosis Cell Death Weak Apoptosis Cell Death Gastric Adenocarcinoma Colon Adenocarcinoma DR5 Expression Also: pancreatic, lung, breast and prostate tumors, leukemia and lymphoma Examples of TNFr agonism: inducing Death Receptor 5 b
Slide 26: DR5: IgM Superior In Vitro to IgG
DR5: IgM Superior In Vitro to IgG Cell line killing comparison in vitro of IgG and IgM DR5 antibodies with five different binding domains
Slide 27: Anti-DR5 IgM Antibodies Penetrate Tumors and Rapidly Induce Apoptosis
DR5-IgM DR5-IgG Cleaved Caspase-3 at 1 hour Colo205 Tumors Anti-DR5 IgM Antibodies Penetrate Tumors and Rapidly Induce Apoptosis After a Single Dose
Slide 28: DR5: IGM-8444 In Vivo Mouse Xenograft Study
6/10 tumor free IGM-8444 (5 mg/kg) DR5 IHC DR5: IGM-8444 In Vivo Mouse Xenograft Study
Slide 29: DR5: IGM-8444 In Vivo Combination with Irinotecan
IGM-8444 (5 mg/kg Q2D x 7); Irinotecan (100 mg/kg QW x 3) DR5: IGM-8444 In Vivo Combination with Irinotecan
Slide 30: DR5: IGM-8444 In Vivo Combination with Venetoclax
Non-Hodgkin’s Lymphoma Model (DOHH-2) DR5: IGM-8444 In Vivo Combination with Venetoclax Acute Myeloid Leukemia Model (MV-411) IGM-8444 (5 mg/kg Q2D x 11); Venetoclax (100 mg/kg QD x 21)
Slide 31: IGM-8444 Designed to Optimize Cancer Cell Killing With Minimal Hepatocyte Toxicity
IGM-8444 Designed to Optimize Cancer Cell Killing With Minimal Hepatocyte Toxicity TRAIL vs. IGM-8444 IGM-8444 Affinity, avidity, clustering, DR5 epitope, multimerizing kinetics and exposure all contribute to optimization
Slide 32: IGM-8444 Phase 1: All-comers Solid Tumors and Heme
Phase 1 Standard 3+3 design All-comers solid tumor escalation as monotherapy and in combination with chemotherapy Dosing q2week (with flexibility to test additional schedules) DLT window d1-28 (Cycle 1) IGM 8444 0.3 mg/kg IGM 8444 1.0 mg/kg IGM 8444 IGM 8444 IGM 8444 0.3 mg/kg + FOLFIRI IGM 8444 + F
Slide 33: Targeting IL-15 Delivery to PD-L1 Expressing Tumors with an IgM
Targeting IL-15 Delivery to PD-L1 Expressing Tumors with an IgM Targets and blocks PD-L1 on tumor cells and APCs, inhibits PD-1 signaling (avoids immune suppression) and delivers active IL-15 to tumor infiltrating lymphocytes
Slide 34: IL-15 x PD-L1: In Vitro CD8 T cell Induced Tumor Cytotoxicity
IL-15 x PD-L1 IgM; PD-L1 IgM Cytotoxicity IFNg levels IL-15 x PD-L1: In Vitro CD8 T cell Induced Tumor Cytotoxicity
Slide 35: IL-15 x PD-L1: In Vivo Efficacy and Immune Memory
Vehicle; IL-15 x PD-L1 IgM dosed Q2Dx3 at 5 mg/kg Initial treatment of CT26 tumor CT26 tumor rechallenge 8/10 TF 1/11 TF IL-15 x PD-L1: In Vivo Efficacy and Immune Memory
Slide 36: Potential Applications of IgM Antibody Technology Platform
Potential Applications of IgM Antibody Technology Platform T cell Engager Receptor Cross-linking Agonist Targeted Cytokines Antibody Drug Conjugates Therapeutic Areas Oncology Infectious Disease Autoimmune Disease
Slide 37: Multiple Catalysts Anticipated Through Year-End 2021
Multiple Catalysts Anticipated Through Year-End 2021 IGM-2323 Completion of enrollment in Phase 1 dose escalation study Establishment of recommended Phase 2 dose IGM-8444 Release of initial clinical data from Phase 1 study IGM-7354 Filing of IND Manufacturing Capabilities Commencement of operations
Slide 38: Leadership Team
DANIEL S. CHEN, MD, PhD Chief Medical Officer MISBAH TAHIR Chief Financial Officer ELIZABETH HAANES, PhD VP, Intellectual Property FRED M. SCHWARZER Chief Executive Officer BRUCE KEYT, PhD Chief Scientific Officer WAYNE GODFREY, MD VP, Clinical Development SUZETTE TAUBER VP, Human Resources ANGUS SI
Slide 39: Pioneering the Development of Engineered IgM Antibodies
Pioneering the Development of Engineered IgM Antibodies Corporate Presentation December 2020
IGM Biosciences — Investor Presentation (December 2020) on 6ix